August 22, 2013
One of the biggest AIA changes to affect patent examiners (and applicants) is the transition from a first-to-invent to a first-inventor-to-file system. To assist with this transition, the USPTO has been rolling out a series of examiner training materials along with a training timeline that outlines training programs that extend into FY 2014. The latest training materials provide in-depth explanations and examples for an examiner to analyze the novelty of a claimed invention.
Of particular note, the training materials include a “FITF Comprehensive Training Definition Sheet” that defines key AIA terms. Among those terms is the “effective filing date.” The first step in the novelty analysis is determining the effective filing date of the claimed invention, which is determined on a claim-by-claim basis. The materials define effective filing date for AIA applications (other than reissue applications) as the earlier of the actual filing date of the application or (2) the filing date of the earliest application for which the application is entitled to a right of foreign priority or the domestic benefit of the earlier filing.
The training materials also include a presentation addressing prior art under the AIA. The presentation outlines the statutory framework and shows how the availability of a disclosure as prior art depends on the effective filing date of the claimed invention. 35 U.S.C. §§ 102(a)(1) and 102(a)(2) identify the two types of prior art, and § 102(b) provides exceptions to each category. While most practitioners and examiners are generally familiar with §§ 102(a) and 102(b), the training materials provide concrete examples that illustrate the specifics of applying these rules.
The training materials provide a useful guide to examiners and practitioners alike in navigating the complexities of prior art rejections under the AIA, particularly as the first few Office actions for applications filed under the first-inventor-to-file system are issued and addressed in the coming months.
Copyright © 2013 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. Additional disclaimer information.
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.